Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.

Informational Articles

  • Which is the Best for you? Mastectomy or Lumpectomy Procedure
    Breast cancer treatment is easy to select if there are several tumors. However, if you have one tumor, you have more than one treatment option available. Physicians provide guidance on the available treatments and help you to decide on the best method for you. If you are currently struggling to choose the right treatment, here […]
  • How Does Breast Cancer Affect COVID-19 Risks?
    According to the World Health Organization, Coronavirus related death rate for cancer patients is 7.6%. Breast cancer patients currently under care or those who recently completed their treatment face a higher risk of contracting Sars-Cov-2. Below are some ways which increase the risk of breast cancer for patients. Reasons for Increased Risk Covid-19 symptoms in […]
  • Incidence and Treatment of Colorectal Cancer
    Colorectal cancer is the second most rampant cancer in women, the third most common for men, and the third most widespread cancer in the world. Risk factors for colorectal cancer include consumption of processed meat, sedentary life, low consumption of fiber or calcium, excess body weight, aging, smoking, and consumption of alcohol. Colorectal cancer is […]
  • Non-Smokers are Likely to Respond Differently to Lung Cancer Treatment
      The Institute of Cancer Research (ICR) reports that lung cancer in non-smokers and smokers varies, and it responds differently to various forms of treatment. The research conducted in Taiwan shows that tumors among non-smokers had genetic changes that varied depending on the patient’s age or sex. Many lung cancer patients (non-smokers) had signs of […]
  • When Metastatic Lung Cancer Patients Should Stop Using Immunotherapy
    Metastatic lung cancer patients should continue with immunotherapy for up to 2 years if they are responsive and are not experiencing excessive toxicity or disease progression. Initially, stage III lung cancer patients usually undergo immunotherapy for one year as established in one clinical trial. The trial results showed that durvalumab (imfinzi) could prolong overall survival […]

More Choice Cancer Care Centers